Rigorous Validation for Clinical Confidence
At SADI Inc., we believe that the true measure of AI in healthcare is its proven ability to perform reliably and effectively in real-world clinical settings. Our commitment to rigorous validation is unwavering, encompassing ongoing pilot studies, collaborations with leading medical institutions, and a data-driven approach to demonstrating the tangible benefits of our platform.
We are dedicated to transparency and evidence-based medicine, ensuring that clinicians can trust SADI to enhance their diagnostic capabilities and improve patient outcomes.
Ongoing Pilot Programs & Field Testing
SADI's technology is actively deployed and evaluated in diverse healthcare environments globally.
Rajasthan, India
Extensive field trials in rural and urban clinics focusing on SADI-M's diagnostic support for common infectious diseases (like COVID-19 & Pneumonia from X-rays) and SADI-MGPT's offline capabilities in low-resource settings. Emphasis on multilingual support and usability.
Nairobi, Kenya & Rural Africa
Deployment of offline RTX 5090 laptop solutions in partnership with NGOs. Focus on conditions prevalent in Sub-Saharan Africa, including ophthalmological screening (e.g., diabetic retinopathy) and point-of-care ultrasound assistance.
New York City, USA
Validation partnerships with major U.S. medical systems, focusing on integrating SADI-MGPT into existing EHR workflows for decision support, and SADI-M for specialized imaging analysis in oncology and neurology departments.
These pilots provide invaluable data on performance, usability, and integration challenges, allowing us to continuously refine our platform for maximum clinical utility.
Key Clinical Use Cases & Impact Metrics
Illustrating SADI's transformative potential across various medical specialties.
Radiology & Imaging Triage
SADI-M assists in rapidly triaging chest X-rays, CT scans, and MRIs, highlighting potential abnormalities for prioritized review. SADI-MGPT helps draft preliminary reports and summarize findings.
Impact: Pilots indicate up to a 40% reduction in radiology report turnaround time for critical cases.
Ophthalmology Screening
Detection of early indicators of conditions like diabetic retinopathy and macular degeneration from retinal fundus images, enabling timely intervention in underserved populations using portable SADI-M deployments.
Impact: Increased screening accessibility by 300% in pilot rural areas.
Pathology & Oncology Support
AI-assisted analysis of histopathology slides for malignancy grading and cell-type classification. SADI-MGPT aids in correlating pathology reports with genomic data for personalized oncology.
Impact: In a pilot study, SADI-M helped identify 14 previously overlooked early-stage cancer indicators in a 3-month period.
Neurology & Stroke Care
Rapid analysis of brain MRIs/CTs for detecting signs of stroke or tumors. SADI-MGPT provides decision support for acute neurological emergencies, referencing latest treatment guidelines.
Impact: Contributed to a 15-minute reduction in door-to-needle time for stroke patients in a partner ER.
Cardiology & Risk Assessment
SADI-M analyzes echocardiograms or cardiac MRIs for abnormalities, while SADI-MGPT assists in assessing cardiovascular risk by integrating patient history, lab results, and lifestyle factors, aiding in preventative care strategies.
Impact: Enhanced early identification of high-risk cardiac patients by 25% in preliminary evaluations.
Emergency Medicine & Trauma
In high-pressure ER settings, SADI provides rapid analysis of trauma imaging (e.g., FAST scans, portable X-rays) and SADI-GPTM offers quick access to critical care protocols and supports documentation, especially in mass casualty incidents.
Impact: Streamlined initial trauma assessment, potentially reducing decision time by several critical minutes.
Research & Publications
Our commitment to advancing medical AI through peer-reviewed research and transparent methodologies.
SADI Inc. actively contributes to the scientific community. While many of our core algorithms and datasets remain proprietary during active development and patenting, we are committed to publishing validation studies, methodology papers, and ethical considerations related to our work. (Currently, specific DOIs are placeholder and will be updated as studies are published).
-
"Evaluating Multimodal AI (SADI-MGPT) for Diagnostic Accuracy in Complex Cases: A Multi-Center Pilot Study." (In Preparation, Target Journal: JAMA Internal Medicine, 2025)
Anticipated DOI: [Placeholder]
-
"Offline AI for Resource-Limited Settings: Field Validation of SADI-M on RTX 5090 Laptops in Rural India." (Submitted, Target Journal: The Lancet Digital Health, 2024)
Preprint DOI: [Placeholder]
-
"Ethical Framework for Deployable Medical LLMs: Ensuring Safety and Equity with SADI-MGPT." (Conference Proceeding, AI for Global Health Summit, 2024)
DOI: [Placeholder]
What Clinicians & Partners Are Saying
Feedback from those experiencing SADI's capabilities firsthand.
Commitment to Regulatory Excellence
Building SADI for real-world clinical use, not just academic benchmarks, requires a steadfast commitment to regulatory standards and patient safety.
Our validation processes are designed in alignment with guidelines from leading regulatory bodies. We are proactively engaging in pathways for:
- FDA (U.S.) Engagement: Pursuing 510(k) and De Novo classification pathways for specific SADI-M and SADI-MGPT functionalities.
- CE Marking (Europe): Ensuring compliance with EU Medical Device Regulation (MDR) and active pursuit of ISO 13485 certification for our quality management system.
- CDSCO (India) Compliance: Aligning with requirements for software-based medical devices (Class C) for deployment within the Indian healthcare system.
- Global Standards: Adherence to ISO 27001 (Information Security) and HIPAA (Patient Privacy) frameworks across all deployments.
- Traceability & Audit: Built-in logging, audit trails, and version control for AI models and data, designed for transparency and accountability.
- Proactive Risk Management: Implementing comprehensive risk analysis and mitigation strategies throughout the product lifecycle, aligned with ISO 14971.
Our goal is to achieve certified global deployment for key diagnostic modules by 2027, ensuring SADI meets the highest standards of safety, efficacy, and quality.